Skip to main navigation menu Skip to main content Skip to site footer
Cortica

Articles

Vol. 5 No. 2 (2026): Educationl neurosciences : Supporting young minds in the era of uncertainty

Perspectives hormonales sur les différences genrées et sexuées : un essai sur les profils atypiques des femmes schizophrènes

  • Luna Lorétan
DOI
https://doi.org/10.26034/cortica.2026.11666
Submitted
October 6, 2026
Published
2026-10-09

Abstract

Les différences genrées et sexuées (G/S) contribuent à la forte hétérogénéité clinique des troubles du spectre psychotique, pourtant la question de l’influence endocrinienne reste ouverte. Quatre hormones (testostérone, œstradiol, progestérone, prolactine) ont été étudiées afin d'identifier d'éventuels profils atypiques et sous-groupes cliniques. Le travail de mémoire dont cet essai présente une adaptation, comparait des patient.e.s SCZ et contrôles sur plusieurs variables hormonales au moyen de l’examen des proportions d’hyperprolactinémie présentes dans chaque groupe et de l’hétérogénéité clinique grâce à une analyse par clustering hiérarchique. Conformément à la littérature antérieure, l'hyperprolactinémie était plus fréquente chez les hommes SCZ et tendanciellement plus élevée chez les femmes, malgré une association ténue avec les antipsychotiques. Enfin, l'analyse par clusters a identifié un sous-groupe de femmes présentant des profils cliniques saillants accompagnés de taux d'œstradiol plus faibles, pas mieux expliqués par un effet iatrogène. Pris ensemble, ces résultats soutiennent une vision intégrative et sensible au G/S de la SCZ, éclairée par des analyses endocriniennes, qui souligne l’importance d’ouvrir de nouvelles voies pour les soins personnalisés et des stratégies de traitement sur mesure.

References

  1. Abel, K. M., Drake, R., & Goldstein, J. M. (2010). Sex differences in schizophrenia. International Review of Psychiatry, 22(5), 417‑428. https://doi.org/10.3109/09540261.2010.515205
  2. Alliende, L. M., Czepielewski, L. S., Aceituno, D., Castañeda, C. P., Diaz, C., Iruretagoyena, B., Mena, C., Mena, C., Ramirez-Mahaluf, J. P., Tepper, Á., Vasquez, J., Fonseca, L., Machado, V., Hernández, C. E., Vargas-Upegui, C., Gomez-Cruz, G., Kobayashi-Romero, L. F., Moncada-Habib, T., Evans-Lacko, S., … Crossley, N. A. (2022). Gender, age and geographical representation over the past 50 years of schizophrenia research. Psychiatry Research, 307, 114279. https://doi.org/10.1016/j.psychres.2021.114279
  3. Amoretti, S., Mezquida, G., Verdolini, N., Bioque, M., Sánchez-Torres, A. M., Pina-Camacho, L., Zorrilla, I., Trabsa, A., Rodriguez-Jimenez, R., Corripio, I., Sarró, S., Ibañez, A., Usall, J., Segarra, R., Vieta, E., Roberto, N., Ramos-Quiroga, J. A., Tortorella, A., Menculini, G., … Portilla, M. P. (2025). Negative symptoms and sex differences in first episode schizophrenia : What’s their role in the functional outcome? A longitudinal study. Spanish Journal of Psychiatry and Mental Health, 18(2), 91‑99. https://doi.org/10.1016/j.sjpmh.2023.04.001
  4. Ates, M. A., Tutuncu, R., Oner, I., Ercan, S., Basoglu, C., Algul, A., Balibey, H., Ipcioglu, O. M., Cetin, M., & Ebrinc, S. (2015). Relationship Between Plasma Levels of Prolactin and the Severity of Negative Symptoms in Patients with Schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, 25(1), 27‑37. https://doi.org/10.5455/bcp.20141212113905
  5. Babinkostova, Z., Manuseva, N., & Markovic, S. (2022). Correlation Between the Different Types of Antipsychotics and Serum Cortisol, Dehidroepiandrosterone Sulfat and their Ratio in Schizophrenia. PRILOZI, 43(1), 29‑39. https://doi.org/10.2478/prilozi-2022-0003
  6. Bell, C. C. (1994). DSM-IV : Diagnostic and Statistical Manual of Mental Disorders. JAMA: The Journal of the American Medical Association, 272(10), 828. https://doi.org/10.1001/jama.1994.03520100096046
  7. Bell, M., Milstein, R., Beam-Goulet, J., Lysaker, P., & Cicchetti, D. (1992). The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale : Reliability, Comparability, and Predictive Validity. The Journal of Nervous and Mental Disease, 180(11), 723‑728. https://doi.org/10.1097/00005053-199211000-00007
  8. Bem, S. L. (1974). The measurement of psychological androgyny. Journal of Consulting and Clinical Psychology, 42(2), 155‑162. https://doi.org/10.1037/h0036215
  9. Brand, B. A., De Boer, J. N., & Sommer, I. E. C. (2021). Estrogens in schizophrenia : Progress, current challenges and opportunities. Current Opinion in Psychiatry, 34(3), 228‑237. https://doi.org/10.1097/YCO.0000000000000699
  10. Carter, B., Wootten, J., Archie, S., Terry, A. L., & Anderson, K. K. (2022). Sex and gender differences in symptoms of early psychosis : A systematic review and meta-analysis. Archives of Women’s Mental Health, 25(4), 679‑691. https://doi.org/10.1007/s00737-022-01247-3
  11. Cavaleri, D., Capogrosso, C. A., Guzzi, P., Bernasconi, G., Re, M., Misiak, B., Crocamo, C., Bartoli, F., & Carrà, G. (2023). Blood concentrations of anterior pituitary hormones in drug-naïve people with first-episode psychosis : A systematic review and meta-analysis. Psychoneuroendocrinology, 158, 106392. https://doi.org/10.1016/j.psyneuen.2023.106392
  12. Chand, G. B., Dwyer, D. B., Erus, G., Sotiras, A., Varol, E., Srinivasan, D., Doshi, J., Pomponio, R., Pigoni, A., Dazzan, P., Kahn, R. S., Schnack, H. G., Zanetti, M. V., Meisenzahl, E., Busatto, G. F., Crespo-Facorro, B., Pantelis, C., Wood, S. J., Zhuo, C., … Davatzikos, C. (2020). Two distinct neuroanatomical subtypes of schizophrenia revealed using machine learning. Brain, 143(3), 1027‑1038. https://doi.org/10.1093/brain/awaa025
  13. Cuthbert, B. N., & Morris, S. E. (2021). Evolving Concepts of the Schizophrenia Spectrum : A Research Domain Criteria Perspective. Frontiers in Psychiatry, 12, 641319. https://doi.org/10.3389/fpsyt.2021.641319
  14. Da Silva, T. L., & Ravindran, A. V. (2015). Contribution of sex hormones to gender differences in schizophrenia : A review. Asian Journal of Psychiatry, 18, 2‑14. https://doi.org/10.1016/j.ajp.2015.07.016
  15. Delgado-Alvarado, M., Tordesillas-Gutierrez, D., Ayesa-Arriola, R., Canal, M., De La Foz, V. O.-G., Labad, J., & Crespo-Facorro, B. (2019). Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients. Archives of Women’s Mental Health, 22(3), 367‑373. https://doi.org/10.1007/s00737-018-0899-x
  16. Garcia-Dias, R., Vieira, S., Lopez Pinaya, W. H., & Mechelli, A. (2020). Clustering analysis. In Machine Learning (p. 227‑247). Elsevier. https://doi.org/10.1016/B978-0-12-815739-8.00013-4
  17. Gellert, B., Ostrowski, J., Pinkas, J., & Religioni, U. (2025). Underdiagnosed and Misunderstood : Clinical Challenges and Educational Needs of Healthcare Professionals in Identifying Autism Spectrum Disorder in Women. Behavioral Sciences, 15(8), 1073. https://doi.org/10.3390/bs15081073
  18. Gleeson, P. C., Worsley, R., Gavrilidis, E., Nathoo, S., Ng, E., Lee, S., & Kulkarni, J. (2016). Menstrual cycle characteristics in women with persistent schizophrenia. Australian & New Zealand Journal of Psychiatry, 50(5), 481‑487. https://doi.org/10.1177/0004867415590459
  19. Goh, K. K., Chen, C.-H., & Lane, H.-Y. (2021). Oxytocin in Schizophrenia : Pathophysiology and Implications for Future Treatment. International Journal of Molecular Sciences, 22(4), 2146. https://doi.org/10.3390/ijms22042146
  20. Guloksuz, S., & Van Os, J. (2018). The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychological Medicine, 48(2), 229‑244. https://doi.org/10.1017/S0033291717001775
  21. Haavik, L., Joa, I., Hatloy, K., Stain, H. J., & Langeveld, J. (2019). Help seeking for mental health problems in an adolescent population : The effect of gender. Journal of Mental Health, 28(5), 467‑474. https://doi.org/10.1080/09638237.2017.1340630
  22. Hamers, I. M. H., Brand, B. A., Begemann, M. J. H., Weickert, C. S., Weickert, T. W., & Sommer, I. E. C. (2024). The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder : Divergent effects of testosterone and estrogen. Schizophrenia Research, 270, 273‑280. https://doi.org/10.1016/j.schres.2024.06.022
  23. Hjelmervik, H., Hausmann, M., Bless, J. J., Harkestad, N., Hugdahl, K., & Laloyaux, J. (2024). Estradiol driven change in hallucination proneness across the menstrual cycle as studied with a white noise paradigm. Psychoneuroendocrinology, 159, 106410. https://doi.org/10.1016/j.psyneuen.2023.106410
  24. Hoekstra, S., Bartz-Johannessen, C., Sinkeviciute, I., Reitan, S. K., Kroken, R. A., Løberg, E.-M., Larsen, T. K., Rettenbacher, M., Johnsen, E., & Sommer, I. E. (2021). Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder : Results from the BeSt InTro study. Npj Schizophrenia, 7(1), 39. https://doi.org/10.1038/s41537-021-00170-3
  25. Ittig, S., Studerus, E., Heitz, U., Menghini-Müller, S., Beck, K., Egloff, L., Leanza, L., Andreou, C., & Riecher-Rössler, A. (2017). Sex differences in prolactin levels in emerging psychosis : Indication for enhanced stress reactivity in women. Schizophrenia Research, 189, 111‑116. https://doi.org/10.1016/j.schres.2017.02.010
  26. Ivanova, S. A., Osmanova, D. Z., Boiko, A. S., Pozhidaev, I. V., Freidin, M. B., Fedorenko, O. Yu., Semke, A. V., Bokhan, N. A., Kornetova, E. G., Rakhmazova, L. D., Wilffert, B., & Loonen, A. J. M. (2017). Prolactin gene polymorphism (− 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophrenia Research, 182, 110‑114. https://doi.org/10.1016/j.schres.2016.10.029
  27. JASP Team (2024). JASP, Version 0.95.1, https://jasp-stats.org/
  28. Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin, 13(2), 261‑276. https://doi.org/10.1093/schbul/13.2.261
  29. Kelly, D. L., Rowland, L. M., Patchan, K. M., Sullivan, K., Earl, A., Raley, H., Liu, F., Feldman, S., & McMahon, R. P. (2016). Schizophrenia clinical symptom differences in women vs. Men with and without a history of childhood physical abuse. Child and Adolescent Psychiatry and Mental Health, 10(1), 5. https://doi.org/10.1186/s13034-016-0092-9
  30. Krysta, K., Bratek, A., Koźmin-Burzyńska, A., & Krupka-Matuszczyk, I. (2016). Serum hormone levels and cognitive functioning in male schizophrenia patients. European Psychiatry, 33(S1), s256‑s256. https://doi.org/10.1016/j.eurpsy.2016.01.650
  31. Kulkarni, J. (1997). Women and Schizophrenia : A Review. Australian & New Zealand Journal of Psychiatry, 31(1), 46‑56. https://doi.org/10.3109/00048679709073798
  32. Labad, J. (2019). The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders. Psychoneuroendocrinology, 102, 24‑36. https://doi.org/10.1016/j.psyneuen.2018.11.028
  33. Lakis, N., Jiménez, J. A., Mancini-Marïe, A., Stip, E., Lavoie, M. E., & Mendrek, A. (2011). Neural correlates of emotional recognition memory in schizophrenia : Effects of valence and arousal. Psychiatry Research: Neuroimaging, 194(3), 245‑256. https://doi.org/10.1016/j.pscychresns.2011.05.010
  34. Leach, L. S., Christensen, H., Mackinnon, A. J., Windsor, T. D., & Butterworth, P. (2008). Gender differences in depression and anxiety across the adult lifespan : The role of psychosocial mediators. Social Psychiatry and Psychiatric Epidemiology, 43(12), 983‑998. https://doi.org/10.1007/s00127-008-0388-z
  35. Lee, B. H., Eid, R. S., Hodges, T. E., Barth, C., & Galea, L. A. M. (2025). Leveraging research into sex differences and steroid hormones to improve brain health. Nature Reviews Endocrinology, 21(4), 214‑229. https://doi.org/10.1038/s41574-024-01061-0
  36. Lokeshwar, S. D., Patel, P., Fantus, R. J., Halpern, J., Chang, C., Kargi, A. Y., & Ramasamy, R. (2021). Decline in Serum Testosterone Levels Among Adolescent and Young Adult Men in the USA. European Urology Focus, 7(4), 886‑889. https://doi.org/10.1016/j.euf.2020.02.006
  37. Longenecker, J., Genderson, J., Dickinson, D., Malley, J., Elvevåg, B., Weinberger, D. R., & Gold, J. (2010). Where have all the women gone? Schizophrenia Research, 119(1‑3), 240‑245. https://doi.org/10.1016/j.schres.2010.03.023
  38. Markham, J. A. (2012). Sex steroids and schizophrenia. Reviews in Endocrine and Metabolic Disorders, 13(3), 187‑207. https://doi.org/10.1007/s11154-011-9184-2
  39. Mazza, M., Caroppo, E., De Berardis, D., Marano, G., Avallone, C., Kotzalidis, G. D., Janiri, D., Moccia, L., Simonetti, A., Conte, E., Martinotti, G., Janiri, L., & Sani, G. (2021). Psychosis in Women : Time for Personalized Treatment. Journal of Personalized Medicine, 11(12), 1279. https://doi.org/10.3390/jpm11121279
  40. Medina-Loera, S., Flores-Medina, Y., Escamilla-Orozco, R. I., Saracco-Álvarez, R. A., Rosel-Vales, M., Flores-Ramos, M., & Mondragón-Maya, A. (2020). Association between prolactin serum levels and cognitive function in chronic schizophrenia patients. Salud Mental, 43(1), 21‑25. https://doi.org/10.17711/SM.0185-3325.2020.004
  41. Mendrek, A., Bourque, J., Dubé, A., Lakis, N., & Champagne, J. (2012). Emotion Processing in Women with Schizophrenia Is Menstrual Cycle Phase and Affective Valence Dependent : An fMRI Study. ISRN Psychiatry, 2012, 1‑13. https://doi.org/10.5402/2012/656274
  42. Mendrek, A., Lakis, N., & Jiménez, J. (2011). Associations of sex steroid hormones with cerebral activations during mental rotation in men and women with schizophrenia. Psychoneuroendocrinology, 36(9), 1422‑1426. https://doi.org/10.1016/j.psyneuen.2011.03.016
  43. Mirzakhanian, H., Singh, F., & Cadenhead, K. S. (2014). Biomarkers in Psychosis : An Approach to Early Identification and Individualized Treatment. Biomarkers in Medicine, 8(1), 51‑57. https://doi.org/10.2217/bmm.13.134
  44. Misiak, B., Frydecka, D., Loska, O., Moustafa, A. A., Samochowiec, J., Kasznia, J., & Stańczykiewicz, B. (2018). Testosterone, DHEA and DHEA-S in patients with schizophrenia : A systematic review and meta-analysis. Psychoneuroendocrinology, 89, 92‑102. https://doi.org/10.1016/j.psyneuen.2018.01.007
  45. Montalvo, I., Nadal, R., Armario, A., Gutiérrez-Zotes, A., Creus, M., Cabezas, Á., Solé, M., Algora, M. J., Sánchez-Gistau, V., Vilella, E., & Labad, J. (2018). Sex differences in the relationship between prolactin levels and impaired processing speed in early psychosis. Australian & New Zealand Journal of Psychiatry, 52(6), 585‑595. https://doi.org/10.1177/0004867417744254
  46. Murata, E. M., Pritschet, L., Grotzinger, H., Taylor, C. M., & Jacobs, E. G. (2024). Circadian rhythms tied to changes in brain morphology in a densely-sampled male. The Journal of Neuroscience, e0573242024. https://doi.org/10.1523/JNEUROSCI.0573-24.2024
  47. Na, K.-S., Jung, H.-Y., & Kim, Y.-K. (2014). The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 48, 277‑286. https://doi.org/10.1016/j.pnpbp.2012.10.022
  48. Nolan, C. J., Roepke, T. A., & Perreault, M. L. (2023). Beyond the Binary : Gender Inclusivity in Schizophrenia Research. Biological Psychiatry, 94(7), 543‑549. https://doi.org/10.1016/j.biopsych.2023.03.018
  49. Noyan, H., Hamamci, A., Firat, Z., Sarsilmaz, A., & Ucok, A. (2022). Menstrual Cycle-Related Changes in Women with Schizophrenia : A Resting-State fMRI Study. Neuropsychobiology, 81(4), 296‑310. https://doi.org/10.1159/000522002
  50. Oldfield, R. C. (1971). The assessment and analysis of handedness : The Edinburgh inventory. Neuropsychologia, 9(1), 97‑113. https://doi.org/10.1016/0028-3932(71)90067-4
  51. Overall, J. E., & Gorham, D. R. (2012). Brief Psychiatric Rating Scale [Jeu de données]. https://doi.org/10.1037/t01554-000
  52. Patel, P. K., Leathem, L. D., Currin, D. L., & Karlsgodt, K. H. (2021). Adolescent Neurodevelopment and Vulnerability to Psychosis. Biological Psychiatry, 89(2), 184‑193. https://doi.org/10.1016/j.biopsych.2020.06.028
  53. Petrikis, P., Tigas, S., Tzallas, A. T., Karampas, A., Papadopoulos, I., & Skapinakis, P. (2020). Sex hormone levels in drug-naïve, first-episode patients with psychosis. International Journal of Psychiatry in Clinical Practice, 24(1), 20‑24. https://doi.org/10.1080/13651501.2019.1699117
  54. Posit team (2024). RStudio: Integrated Development Environment for R. Posit Software, PBC, Boston. http://www.posit.co/.
  55. Potvin, S., Lungu, O., Tikàsz, A., & Mendrek, A. (2017). Abnormal effective fronto-limbic connectivity during emotion processing in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 72, 1‑8. https://doi.org/10.1016/j.pnpbp.2016.08.004
  56. Rajkumar, R. P. (2014). Prolactin and Psychopathology in Schizophrenia : A Literature Review and Reappraisal. Schizophrenia Research and Treatment, 2014, 1‑12. https://doi.org/10.1155/2014/175360
  57. Reale, M., Costantini, E., & Greig, N. H. (2021). Cytokine Imbalance in Schizophrenia. From Research to Clinic : Potential Implications for Treatment. Frontiers in Psychiatry, 12, 536257. https://doi.org/10.3389/fpsyt.2021.536257
  58. Reilly, T. J., Sagnay De La Bastida, V. C., Joyce, D. W., Cullen, A. E., & McGuire, P. (2020). Exacerbation of Psychosis During the Perimenstrual Phase of the Menstrual Cycle : Systematic Review and Meta-analysis. Schizophrenia Bulletin, 46(1), 78‑90. https://doi.org/10.1093/schbul/sbz030
  59. Riecher-Rössler, A., Butler, S., & Kulkarni, J. (2018). Sex and gender differences in schizophrenic psychoses—A critical review. Archives of Women’s Mental Health, 21(6), 627‑648. https://doi.org/10.1007/s00737-018-0847-9
  60. Rodefer, J. S., Castleberry, A. L., & Whitaker, B. M. (2022). A Systematic Review of the Involvement of Progesterone in Schizophrenia.
  61. Rossetti, M. F., Cambiasso, M. J., Holschbach, M. A., & Cabrera, R. (2016). Oestrogens and Progestagens : Synthesis and Action in the Brain. Journal of Neuroendocrinology, 28(7), jne.12402. https://doi.org/10.1111/jne.12402
  62. Schnack, H. G. (2019). Improving individual predictions : Machine learning approaches for detecting and attacking heterogeneity in schizophrenia (and other psychiatric diseases). Schizophrenia Research, 214, 34‑42. https://doi.org/10.1016/j.schres.2017.10.023
  63. Segarra, R., Ojeda, N., Zabala, A., García, J., Catalán, A., Eguíluz, J. I., & Gutiérrez, M. (2012). Similarities in early course among men and women with a first episode of schizophrenia and schizophreniform disorder. European Archives of Psychiatry and Clinical Neuroscience, 262(2), 95‑105. https://doi.org/10.1007/s00406-011-0218-2
  64. Sinclair, D., Purves-Tyson, T. D., Allen, K. M., & Weickert, C. S. (2014). Impacts of stress and sex hormones on dopamine neurotransmission in the adolescent brain. Psychopharmacology, 231(8), 1581‑1599. https://doi.org/10.1007/s00213-013-3415-z
  65. Sisek-Šprem, M., Križaj, A., Jukić, V., Milošević, M., Petrović, Z., & Herceg, M. (2015). Testosterone levels and clinical features of schizophrenia with emphasis on negative symptoms and aggression. Nordic Journal of Psychiatry, 69(2), 102‑109. https://doi.org/10.3109/08039488.2014.947320
  66. Sommer, I. E., Tiihonen, J., Van Mourik, A., Tanskanen, A., & Taipale, H. (2020). The clinical course of schizophrenia in women and men—A nation-wide cohort study. Npj Schizophrenia, 6(1), 12. https://doi.org/10.1038/s41537-020-0102-z
  67. Sosinsky, A. Z., Rich-Edwards, J. W., Wiley, A., Wright, K., Spagnolo, P. A., & Joffe, H. (2022). Enrollment of female participants in United States drug and device phase 1–3 clinical trials between 2016 and 2019. Contemporary Clinical Trials, 115, 106718. https://doi.org/10.1016/j.cct.2022.106718
  68. Statistics Canada, & Employment and Social Development Canada. (2012). National Occupational Classification (NOC) 2011 (Catalogue no. 12-583-X). Statistics Canada
  69. Struszczyk, S., Galdas, P. M., & Tiffin, P. A. (2019). Men and suicide prevention : A scoping review. Journal of Mental Health, 28(1), 80‑88. https://doi.org/10.1080/09638237.2017.1370638
  70. Studerus, E., Ittig, S., Beck, K., Del Cacho, N., Vila-Badia, R., Butjosa, A., Usall, J., & Riecher-Rössler, A. (2021). Relation between self-perceived stress, psychopathological symptoms and the stress hormone prolactin in emerging psychosis. Journal of Psychiatric Research, 136, 428‑434. https://doi.org/10.1016/j.jpsychires.2020.06.014
  71. Sultana, J., Hurtado, I., Bejarano-Quisoboni, D., Giorgianni, F., Huybrechts, K. F., Lu, Z., Patorno, E., Sanfélix-Gimeno, G., Tari, D. U., & Trifirò, G. (2019). Antipsychotic utilization patterns among patients with schizophrenic disorder : A cross-national analysis in four countries. European Journal of Clinical Pharmacology, 75(7), 1005‑1015. https://doi.org/10.1007/s00228-019-02654-9
  72. Toll, A., Bergé, D., Martínez-Sadurní, L., Trabsa, A., Perez-Sola, V., & Mané, A. (2025). Hyperprolactinemia in drug-naïve first episode psychosis and its association with BDNF levels. The European Journal of Psychiatry, 39(3), 100307. https://doi.org/10.1016/j.ejpsy.2025.100307
  73. Tost, M., Armario, A., Barbero, J. D., Cobo, J., García-Rizo, C., Bioque, M., Usall, J., Huerta-Ramos, E., Soria, V., & Labad, J. (2020). Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia : Thyroid Hormones and Prolactin. Clinical Drug Investigation, 40(1), 1‑14. https://doi.org/10.1007/s40261-019-00854-w
  74. Tsuboi, T., Bies, R. R., Suzuki, T., Mamo, D. C., Pollock, B. G., Graff-Guerrero, A., Mimura, M., & Uchida, H. (2013). Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia : Analysis of the CATIE data. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 45, 178‑182. https://doi.org/10.1016/j.pnpbp.2013.05.010
  75. Whitley, R. (2021). Risk Factors and Rates of Depression in Men : Do Males Have Greater Resilience, or Is Male Depression Underrecognized and Underdiagnosed? In R. Whitley, Men’s Issues and Men’s Mental Health (p. 105‑125). Springer International Publishing. https://doi.org/10.1007/978-3-030-86320-3_5
  76. Young, S., Adamo, N., Ásgeirsdóttir, B. B., Branney, P., Beckett, M., Colley, W., Cubbin, S., Deeley, Q., Farrag, E., Gudjonsson, G., Hill, P., Hollingdale, J., Kilic, O., Lloyd, T., Mason, P., Paliokosta, E., Perecherla, S., Sedgwick, J., Skirrow, C., … Woodhouse, E. (2020). Females with ADHD : An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women. BMC Psychiatry, 20(1), 404. https://doi.org/10.1186/s12888-020-02707-9
  77. Yum, S. K., Yum, S. Y., & Kim, T. (2019). The problem of medicating women like the men : Conceptual discussion of menstrual cycle-dependent psychopharmacology. Translational and Clinical Pharmacology, 27(4), 127. https://doi.org/10.12793/tcp.2019.27.4.127